Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Raw Materials (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Raw Materials data on record, last reported at $14.6 million in Q4 2025.

  • For Q4 2025, Raw Materials fell 13.95% year-over-year to $14.6 million; the TTM value through Dec 2025 reached $14.6 million, down 13.95%, while the annual FY2025 figure was $14.6 million, 13.95% down from the prior year.
  • Raw Materials reached $14.6 million in Q4 2025 per MRVI's latest filing, down from $16.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $26.8 million in Q3 2023 and bottomed at $13.5 million in Q4 2022.
  • Average Raw Materials over 5 years is $18.8 million, with a median of $18.4 million recorded in 2021.
  • Peak YoY movement for Raw Materials: surged 77.52% in 2021, then tumbled 37.79% in 2024.
  • A 5-year view of Raw Materials shows it stood at $19.7 million in 2021, then tumbled by 31.63% to $13.5 million in 2022, then skyrocketed by 43.39% to $19.3 million in 2023, then decreased by 12.22% to $17.0 million in 2024, then dropped by 13.95% to $14.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $14.6 million in Q4 2025, $16.0 million in Q3 2025, and $16.4 million in Q2 2025.